BUSINESS

• Anticancer Peptide-Drug Conjugates Could Overcome Problems with ADCs: PeptiDream
  February 9, 2016

• PeptiDream Joins Hands with Shionogi, 5th Japanese Partner
  February 8, 2016

• Takeda Expands ADC Collaboration with US Startup Mersana
  February 5, 2016

• FDA Panel Backs Effectiveness of Brintellix for Cognitive Dysfunction
  February 5, 2016

• Mitsubishi Tanabe to Establish Stand-Alone Sales Structure via New US Subsidiary
  February 5, 2016

• BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
  February 5, 2016

• Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
  February 5, 2016

• Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
  February 4, 2016

• Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
  February 4, 2016

• Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
  February 4, 2016

• Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
  February 4, 2016

• Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
  February 4, 2016

• Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
  February 4, 2016

• Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
  February 3, 2016

• Seikagaku, Kaken Call Off Artz Development for Expanded Indication
  February 3, 2016

• Sakigake-Designated NS-065 Now in PI/II: Nippon Shinyaku
  February 3, 2016

• Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
  February 3, 2016

• J-TEC Files Skin-Derived Cell Sheet JACE for Giant Pigmented Nevus
  February 2, 2016

• Pola Pharma to Take Over GSK’s Marketing Authorization for Acne Drug Duac
  February 2, 2016

• Eisai Gets Japan, Asia Rights to HDAC Inhibitor
  February 2, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 493
• 494
• 495
• 496
• 497
• 498
• 499
• 500
• 501
• …
• Next ›
• 最終 »